Aspen RxHealth is a technology company.
Aspen RxHealth has raised $23.0M across 1 funding round.
Aspen RxHealth has raised $23.0M in total across 1 funding round.
Aspen RxHealth has raised $23.0M in total across 1 funding round.
Aspen RxHealth's investors include David Ibnale, Bessemer Venture Partners, Collaborative Seed & Growth Partners, ENIAC Ventures, Next Play Ventures, Obvious Ventures, REMUS Capital.
Aspen RxHealth is a Tampa, Florida-based healthcare technology company founded in 2018 that builds a platform connecting a nationwide network of over 7,000 pharmacists with patients to deliver clinical pharmacy services.[1][2][3][4][5] Its core products, including a mobile app and the web-based BeWell and Alliance platforms, enable medication therapy management (MTM), comprehensive medication reviews (CMRs), targeted medication reviews (TMRs), adherence optimization, and patient education for health plans, provider groups, life sciences companies, and strategic partners.[2][3][4][5][6] The company solves key problems in medication management—such as poor adherence, high healthcare costs, and underutilized pharmacist expertise—by using proprietary algorithms to match pharmacists with patients based on clinical, social, geographic, and demographic factors, allowing remote, flexible, CMS-compliant consultations that improve outcomes and reduce costs.[1][3][5][7] Following a $9 million Series A in 2018, Aspen RxHealth has gained traction with major health plans, scaling its pharmacist community and launching solutions like Alliance in 2022 to empower in-house teams.[1][5][6]
Aspen RxHealth emerged in 2018 from founders David (last name not specified in sources) and a co-founding team of pharmacists and healthcare experts who recognized pharmacists' untapped potential amid advances in pharmacy workflow automation but persistent gaps in direct patient care.[1][5] Driven by a vision to reestablish the patient-pharmacist relationship through technology, the company launched with a mobile app-based intervention platform backed by a $9 million Series A led by Flare Capital Partners' Michael Greeley, who highlighted improved interoperability enabling pharmacists as care team cornerstones.[1] Early traction came from crowdsourcing a two-sided marketplace of pharmacists and patients, focusing on MTM services, with pivotal growth including the 2022 debut of Alliance by Aspen RxHealth to support health plans' in-house teams.[1][5][6]
Aspen RxHealth rides the wave of value-based care and digital health transformation, capitalizing on rising demands for cost-effective chronic disease management amid medication non-adherence costing the U.S. healthcare system hundreds of billions annually.[1][2][3] Its timing aligns with post-2018 interoperability advances and CMS incentives for MTM, positioning pharmacists as accessible, scalable care extenders in fragmented systems strained by provider shortages.[1][3][6] Market forces like health plans' shift to proactive adherence for conditions like diabetes and hypertension favor its model, which cuts costs while boosting efficiency over homegrown platforms.[5][6] By overhauling pharmacy from reactive dispensing to proactive, tech-enabled consultations, Aspen RxHealth influences the ecosystem by expanding pharmacist roles, fostering payer-provider collaborations, and competing with AI-driven players like Arine while differentiating through human-centered matching.[4][5]
Aspen RxHealth is poised to expand its pharmacist network and Alliance platform, targeting more health plans with AI-enhanced matching and hybrid in-house/remote models to capture growing MTM and adherence markets.[3][5][6] Trends like AI integration in clinical decision support, rising telepharmacy adoption, and payer focus on social determinants will propel its growth, potentially through further funding or partnerships with life sciences firms.[1][2][4] Its influence may evolve by standardizing pharmacist-led interventions nationwide, driving broader ecosystem shifts toward preventive, patient-centric care that unlocks the full power of this underutilized workforce.[1][5] This positions Aspen RxHealth as a key enabler in medication management's next era, directly advancing its founding mission of unsurpassed patient outcomes.
Aspen RxHealth has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $23.0M Series B | David Ibnale, Bessemer Venture Partners, Collaborative Seed & Growth Partners, ENIAC Ventures, Next Play Ventures, Obvious Ventures, REMUS Capital |